Phase Ib trial of Atu027 in Combination With Cisplatin, 5FU and Cetuximab in Patients With Head and Neck Cancer

Trial Profile

Phase Ib trial of Atu027 in Combination With Cisplatin, 5FU and Cetuximab in Patients With Head and Neck Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs ATU 027 (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Acronyms PACiFiC
  • Most Recent Events

    • 02 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per United Kingdom Clinical Research Network.
    • 15 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top